COMPANY PROFILE

Evozyne

Explore full profile

Generative AI-powered drug discovery platform and product development

Chicago, United StatesFounded 2020Biotech & Life Sciences

Valuation $250–500M Last recorded · 2023

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Evozyne

Evozyne is a pioneering biotech startup focused on creating novel protein systems to address some of the world's most pressing health challenges. The company leverages the natural principles of evolution to develop advanced proteins, which they refer to as "Natural Machines." These proteins are designed to perform specific functions at an unprecedented level of efficiency, paving the way for new therapeutic solutions and commercial-scale applications.

Evozyne primarily serves clients in the pharmaceutical and biotechnology sectors, including companies involved in drug discovery and development. By offering innovative protein solutions, Evozyne aims to enhance the efficacy and safety of therapeutic products, thereby contributing to a healthier world.

Operating in the highly specialized market of protein engineering and synthetic biology, Evozyne stands out due to its unique approach of using evolutionary principles to solve complex biological problems. This market is characterized by rapid advancements and high demand for cutting-edge solutions that can address unmet medical needs.

Evozyne's business model revolves around research and development (R&D) and strategic partnerships. The company invests heavily in R&D to continuously innovate and refine its protein systems. Revenue is generated through collaborations with pharmaceutical companies, licensing agreements, and potentially through the commercialization of proprietary therapeutic products developed using their technology.

The leadership team at Evozyne includes experts with extensive backgrounds in molecular engineering, computational biology, and drug discovery. Their scientific advisory board comprises distinguished professors and researchers from top institutions, ensuring that the company remains at the forefront of scientific innovation.

In summary, Evozyne is a biotech startup that creates advanced protein systems to solve critical health challenges, serving pharmaceutical and biotech clients through a robust R&D-focused business model.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Chicago, United States
Employees: 54
Open positions: 2
Dealroom signal: 70.4/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Spinout, Biotech and Pharma, Generative AI, AI Drug Discovery
Technology: Artificial Intelligence, Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Sep 2023	$81M	$324M	Valor Equity Partners · NVentures · Fidelity Investments · OrbiMed	↗
SERIES AOther financing	Apr 2021	$54M	$217M	Undisclosed	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Evozyne website traffic

Latest recorded traffic for Evozyne is 2.7K monthly website visits, up 35% over the last three months. Evozyne's team grew 0% over the past year.

Latest monthly visits2.7K 3-month web change+35% 1-year team growth0%

Monthly website visitsDec 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Director/Senior Director, Preclinical Program Leadership60602 Chicago, United States · Human Resources · Aug 14, 2026 Data Scientist II, Molecular Biology60602 Chicago, United States · Data Science & Engineering · Jun 21, 2026

2 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PBProxima BioFormerly VantAI. Proximity therapeutics hijacking cellular machinery for protein degradation	New York City, United States	Operational	77	$80M	$320M
SMSuperluminal MedicinesGenerative biology and chemistry company revolutionizing the speed and accuracy of how medicine is created	Boston, United States	Operational
VIVilyaDeveloping a novel class of drugs that precisely target the biology of disease	Seattle, United States	Operational
MAMenten AILeverages synthetic biology, machine learning and quantum computing to create new proteins not found in nature for diverse applications in the pharmaceutical and chemical industries	San Francisco, United States	Operational
GTGenesis TherapeuticsUnifying AI and Biotech We're pairing proven drug developers with the industry's most advanced small molecule discovery platform, to accelerate and optimize the development of new medicines	Burlingame, United States	Operational
ABAbSciThe global leader in cutting-edge protein production technologies committed to reducing costs in the biopharmaceutical industry	Vancouver, United States	Operational
XTXaira TherapeuticsIntegrated biotechnology company focusing on leveraging artificial intelligence to transform drug discovery and development	Brisbane, United States	Operational
AUAutomeratxDeveloping the next evolution in degradation platforms	Singapore	Operational